Locally Advanced or Metastatic Urothelial Carcinoma (UC)
Also known as: Locally Advanced or Metastatic Urothelial Carcinoma
| Drug | Drug Name | Drug Description |
|---|---|---|
| DB13007 | Enfortumab vedotin | An antibody-drug conjugate comprised of a fully human monoclonal antibody and microtubule-disrupting chemotherapeutic agent used in the treatment of advanced or metastatic urothelial cancer. |
| DB12147 | Erdafitinib | A fibroblast growth factor receptor tyrosine kinase inhibitor used to treat locally advanced or metastatic urothelial carcinoma. |
| DB09037 | Pembrolizumab | A PD-1 blocking antibody used to treat various types of cancer, including metastatic melanoma, non small-cell lung cancer, cervical cancer, head and neck cancer, and Hodgkin's lymphoma. |
| DB12893 | Sacituzumab govitecan | Sacituzumab govitecan targets TROP-2-expressing cancer cells through a humanized antibody (RS7) before subsequently becoming internalized and releasing the topoisomerase I inhibitor SN-38 to induce DNA damage-mediated apoptosis. |
| Drug | Drug Name | Phase | Status | Count |
|---|---|---|---|---|
| DB11595 | Atezolizumab | 2 | Completed | 1 |
| DB11945 | Avelumab | 2 | Recruiting | 1 |
| DB00515 | Cisplatin | 2 | Completed | 1 |
| DB00441 | Gemcitabine | 2 | Completed | 1 |
| DB12893 | Sacituzumab govitecan | 2 | Recruiting | 1 |
| DB00958 | Carboplatin | 3 | Not Yet Recruiting | 1 |
| DB00515 | Cisplatin | 3 | Not Yet Recruiting | 1 |
| DB00441 | Gemcitabine | 3 | Not Yet Recruiting | 1 |
| DB15043 | Toripalimab | 3 | Not Yet Recruiting | 1 |
| DB13007 | Enfortumab vedotin | Not Available | Approved for Marketing | 1 |